Changa
Changa is a smokeable psychedelic preparation combining freebase DMT with β-carboline-rich plant material from Banisteriopsis caapi or Peganum harmala.[1] DMT is a potent serotonergic psychedelic — the same compound active in ayahuasca.[2] The β-carbolines block the enzyme that would otherwise destroy inhaled DMT within seconds, extending the experience to 15–40 minutes.[3]
Changa is a smokeable psychedelic preparation combining freebase DMT with β-carboline-containing plant material, most commonly derived from Banisteriopsis caapi or Peganum harmala.[1] Its dominant constituent, DMT, is a full serotonin 2A receptor agonist with a multi-receptor profile distinct from other classical psychedelics.[2] Co-inhaled β-carbolines reversibly inhibit MAO-A, slowing DMT metabolism and extending the psychedelic window from minutes to tens of minutes.[3]
Changa was created by Julian Palmer in Australia in the late 1990s and named around 2003–2004.[4] Palmer adapted ayahuasca's core pharmacology — DMT shielded from breakdown by monoamine oxidase inhibitors — and applied it to the smoking route.[5] No peer-reviewed study documents Changa specifically; all pharmacological and safety data are extrapolated from ayahuasca and pure DMT research.[6]
Subjective effects include vivid geometric visuals, internal hallucinations, apparent entity contact, ego dissolution, and profound temporal distortion.[7] The MAOI component smooths DMT's characteristically abrupt onset into a more gradual emergence with greater narrative continuity than freebase DMT alone. Unwanted effects include overwhelming anxiety at peak intensity, complete disorientation, and loss of control over one's own thoughts.
No physical dependence or withdrawal has been documented for DMT or β-carboline alkaloids.[8] The most serious risk is serotonin syndrome — dangerous overheating and possible seizure — when Changa is combined with antidepressants, a danger compounded by its built-in MAO inhibition.[9] No safety studies cover Changa as a preparation; all risk data are extrapolated from related research, and batch-to-batch potency variation is the main uncontrolled hazard.[6]
History[edit]
Origins
Changa was developed by Julian Palmer, an Australian psychonaut, in the late 1990s.[4] He wanted a form of DMT smokeable through an ordinary pipe or joint, with a gentler onset than pure freebase.[1] He coined the name during an ayahuasca ceremony around 2003–2004; it has no specific etymological origin.[10]
Community adoption
From the mid-2000s, Palmer introduced Changa at festivals across Australia, Europe, Asia, Africa, and South America.[1] The preparation spread through psychedelic subcultures via informal networks and online forums. No peer-reviewed publication documents this diffusion under the name "changa".[11]
Pharmacological foundation
The pharmacological logic behind Changa predates Palmer by over a decade. Researchers established in 1984 that β-carboline alkaloids in B. caapi reversibly block MAO-A, protecting orally consumed DMT from breakdown.[5] A 2015 study confirmed that smoking shifts DMT metabolism from monoamine oxidase to liver enzymes,[6] and clinical trials of vaporized DMT for treatment-resistant depression — the closest scientific structural analog to Changa's route — began in the 2020s.[12][13]
Changa adapts ayahuasca's pharmacology but has no connection to Amazonian indigenous traditions. Traditional ayahuasca — brewed from B. caapi bark with DMT-containing plants — has documented use spanning centuries in the Amazon basin.[14] The common substitution of Peganum harmala for B. caapi is a pragmatic choice: Syrian rue seeds contain higher alkaloid concentrations and are more widely available. This cross-cultural synthesis has no traditional antecedent. citation needed
Botanical Overview[edit]
Component plants
Changa is not a single botanical species but a manufactured preparation combining three components: extracted freebase DMT, β-carboline-containing plant material as the MAOI source, and a carrier herb substrate.[1] The DMT is dissolved in solvent, infused onto the herb blend, and dried. The finished product resembles ordinary dried herb — visually indistinguishable from many herbal smoking blends.
MAOI source plants
Banisteriopsis caapi — the ayahuasca vine (Malpighiaceae) — is a tropical liana from the Amazon basin whose bark contains harmine, harmaline, and tetrahydroharmine.[14] Peganum harmala (Syrian rue, Nitrariaceae), a perennial shrub from the Mediterranean and Central Asia, carries the same β-carboline alkaloids at higher concentrations — making it the more common MAOI source in Western Changa production. Some US states restrict P. harmala cultivation as invasive.[15]
Carrier herbs and identification
The carrier herb substrate varies by recipe with no standardization. Because no commercially produced Changa has been laboratory-tested, the actual botanical composition of any batch is unknown to the end user. Identification by appearance alone is unreliable — color and texture depend on the base herb chosen and the quantity of DMT infused.
Alkaloid Profile[edit]
DMT
DMT (N,N-dimethyltryptamine) is the primary psychoactive constituent. Unlike plant alkaloids with fixed concentrations, DMT content in Changa depends entirely on how much was infused during preparation — community recipes vary widely.[2] DMT activates serotonin pathways in the brain alongside sigma-1 receptors and the trace amine system,[16][17] giving it a broader brain profile than more selective psychedelics like psilocin.[2]
β-Carboline alkaloids
The defining feature of Changa is the co-presence of harmine, harmaline, and tetrahydroharmine (THH) from B. caapi or P. harmala. Harmine and harmaline block MAO-A, the enzyme that normally destroys inhaled DMT in seconds; THH does this more weakly and also slows serotonin reuptake.[5] Co-inhaled, they extend DMT's duration and soften its onset.[3] Beyond enzyme blocking, harmine and harmaline stimulate new brain cell growth in animal models,[18] and harmaline with THH reduce inflammatory signals in brain immune cells.[19]
Variability
Alkaloid concentrations in any batch are inherently unstandardized. P. harmala seeds carry higher β-carboline concentrations than B. caapi bark, and the quantity of MAOI material varies by recipe. No commercially produced Changa has been independently tested, making batch-to-batch potency unpredictable.
Neuroscience[edit]
Where it acts
DMT reaches the brain rapidly through the lungs, bypassing normal first-pass breakdown in the liver. When smoked, liver enzymes (rather than monoamine oxidase) become the primary means of clearing it;[6] co-inhaled β-carbolines further inhibit residual MAO-A in lung and liver tissue.[3] Full activation of serotonin pathways, combined with sigma-1 receptor and trace amine receptor engagement, produces Changa's characteristic content-rich visions and transpersonal states.[2]
What it changes
Research on DMT combined with harmine shows a bidirectional interaction: harmine slows DMT breakdown, while DMT simultaneously alters how harmine behaves.[20] Brain imaging of oral ayahuasca — the closest studied structural analog — shows increased slow-wave activity in emotion and memory regions, quieting of the default mode network, and stimulation of visual association areas.[21] After the acute effects pass, reduced glutamate in the posterior cingulate and increased connectivity to the anterior cingulate correlate with greater mindfulness.[22]
- Whether co-inhaled β-carbolines achieve meaningful systemic MAO-A inhibition, or act mainly in lung tissue, remains uncharacterized.
- The impact of individual variation in liver enzyme activity (CYP2D6) on Changa's duration and intensity has not been studied.
- Whether smoked Changa produces brain changes comparable to oral ayahuasca is unknown.
Subjective Effects[edit]
The Changa experience is shaped primarily by the DMT-to-MAOI ratio in the blend. A high-MAOI preparation produces a longer, more structured arc — gradual onset, sustained narrative coherence — while a low-MAOI blend more closely resembles pure freebase DMT in its abrupt intensity. Inhalation technique matters: deep, sustained draws vaporize DMT more completely than rapid puffs, producing fuller effects at the same dose.
Phenomenologically, Changa sits between freebase DMT and oral ayahuasca. It shares DMT's perceptual intensity and transpersonal depth but compresses ayahuasca's multi-hour arc into a 15–40-minute window. Compared with smoked 5-MeO-DMT — which tends toward undifferentiated ego dissolution — Changa's DMT base characteristically produces structured, content-rich visions and entity-contact phenomena.
Changa was developed by Julian Palmer in Australia during the late 1990s and named in 2003–2004; it has no traditional or indigenous antecedent.[4] Palmer adapted ayahuasca's pharmacological principle — DMT protected by monoamine oxidase inhibition — to the inhalation route, building on research establishing β-carboline MAO-A inhibition.[5] No peer-reviewed publication documents Changa by name; all safety and pharmacokinetic data derive from ayahuasca and pure DMT studies.[6]
Subjective effects include vivid geometric visuals, internal hallucinations, entity contact phenomena, ego dissolution, and temporal distortion.[7] The MAOI component modulates DMT's characteristically abrupt onset into a gentler emergence, affording greater narrative continuity than freebase DMT alone. Unsought effects include overwhelming anxiety at peak intensity, disorientation, and loss of volitional thought control.
No physical dependence or withdrawal has been documented for DMT or β-carboline alkaloids.[8] The primary acute risk is serotonin syndrome when Changa is combined with serotonergic medications, compounded by the preparation's inherent MAO-A inhibition.[9] All safety data are extrapolated from ayahuasca and pure DMT research; batch-to-batch variability in DMT and MAOI content remains the principal uncontrolled risk factor.
History[edit]
Origins
Changa was developed by Julian Palmer, an Australian psychonaut, during the late 1990s.[4] Palmer sought a gentler format for DMT inhalation — one that reduced the abruptness of smoking pure freebase and could be administered via a conventional pipe or joint rather than a glass vapor pipe.[1] He coined the name during an ayahuasca ceremony in 2003–2004; by his own account, the word has no specific etymological origin.[10]
Community adoption
From the mid-2000s, Palmer introduced Changa at festivals and gatherings across Australia, Europe, Asia, Africa, and South America.[1] The preparation spread through psychedelic subcultures via informal networks and online forums, entering harm-reduction databases such as PsychonautWiki and Erowid by the 2010s. No peer-reviewed publication documents this diffusion under the name "changa"; academic literature references smokable DMT with MAOI additives only within broader novel psychoactive substance reviews.[11]
Pharmacological foundation
The pharmacological rationale underlying Changa predates the preparation by over a decade. McKenna, Towers, and Abbott established in 1984 that β-carboline alkaloids in B. caapi function as reversible MAO-A inhibitors, protecting orally administered DMT from first-pass metabolism.[5] The first rigorous pharmacokinetic comparison of oral versus smoked DMT, published in 2015, demonstrated that the smoked route shifts DMT metabolism from monoamine oxidase-dependent to CYP-dependent pathways.[6] Clinical trials of vaporized DMT for treatment-resistant depression, beginning in the 2020s, represent the closest clinical structural analog to Changa's inhalation route.[12][13]
Changa explicitly adapts the ayahuasca pharmacological principle but has no connection to Amazonian indigenous traditions. Traditional ayahuasca — prepared by boiling B. caapi bark with DMT-containing plants such as Psychotria viridis — has documented ethnobotanical use spanning centuries in the Amazon basin.[14] Changa's frequent use of Peganum harmala (Syrian rue) as an MAOI substitute for B. caapi is a pragmatic choice driven by wider availability and higher alkaloid concentration; this cross-cultural synthesis has no traditional antecedent. citation needed
Botanical Overview[edit]
Component plants
Changa is not a single botanical species but a manufactured preparation combining three functional components: extracted freebase DMT, β-carboline-containing MAOI material, and a carrier herb substrate. The freebase DMT is extracted from plant sources, dissolved in a volatile solvent, and infused onto the blended herb material.[1] The resulting product resembles dried, darkened herb — visually indistinguishable from many herbal smoking blends.
MAOI source plants
Banisteriopsis caapi (ayahuasca vine, Malpighiaceae) is a tropical woody liana native to the Amazon basin, traditionally used as the core ingredient in ayahuasca brew.[14] Its bark contains high concentrations of the β-carboline alkaloids harmine, harmaline, and tetrahydroharmine. When used in Changa, B. caapi leaf or vine shavings serve as both the MAOI source and part of the carrier substrate.
Peganum harmala (Syrian rue, Nitrariaceae) is a perennial shrub native to the Mediterranean, Central Asia, and North Africa. Its seeds contain the same β-carboline alkaloid family at higher concentrations than B. caapi bark, making it the more commonly used MAOI source in Western Changa production. Several US states restrict P. harmala cultivation as an invasive species.[15]
Carrier herbs and identification
The carrier herb substrate varies widely by recipe with no standardization. Producers select base herbs for smoking characteristics, flavor, or purported synergistic effects. Because no commercially produced Changa has been subjected to laboratory analysis, the actual botanical composition of any given batch is unknown to the end user. Identification of Changa by appearance alone is unreliable — color and texture depend on the base herb chosen and the quantity of DMT infused.
Alkaloid Profile[edit]
DMT
DMT (N,N-dimethyltryptamine) is the primary psychoactive constituent of Changa. Unlike a naturally occurring plant alkaloid measured as a percentage of dry leaf weight, DMT content in Changa depends entirely on the quantity infused during preparation — community recipes vary widely, and no standardized loading exists. DMT acts as a full agonist at 5-HT₂A receptors and engages sigma-1 receptor,[16][17] 5-HT₁A, and TAAR1 (TAAR1) systems, giving it a broader receptor profile than more selective 5-HT₂A agonists such as psilocin.[2]
β-Carboline alkaloids
The defining pharmacological feature of Changa is the co-presence of β-carboline alkaloids — harmine, harmaline, and tetrahydroharmine (THH) — derived from B. caapi or P. harmala. Harmine and harmaline are potent reversible inhibitors of MAO-A (MAO-A); THH is a weaker MAO-A inhibitor with additional serotonin reuptake inhibitor.[5] In the smoked route, co-inhaled β-carbolines provide local MAO-A inhibition in pulmonary tissue and systemic inhibition in the liver, extending DMT's plasma half-life and producing a longer, more modulated psychedelic experience.[3]
Additional β-carboline activity
Beyond their MAOI function, the β-carbolines demonstrate independent neurobiological effects. Harmine and harmaline stimulate adult neural stem cell proliferation, migration, and differentiation in animal models, suggesting a role in neuroplasticity independent of monoamine oxidase inhibition.[18] Anti-inflammatory effects have been demonstrated in microglial cell models, with harmaline and THH reducing proinflammatory cytokine production.[19]
Variability
Alkaloid concentrations in Changa are inherently unstandardized. DMT loading varies by recipe, with no consensus preparation method or disclosure requirement. MAOI content depends on both the source plant species — P. harmala seeds contain higher β-carboline concentrations than B. caopi bark — and the amount of MAOI material in the blend. No commercially produced Changa has been subjected to independent laboratory analysis, making batch-to-batch potency unpredictable.
Neuroscience[edit]
Where it acts
DMT reaches the brain rapidly via pulmonary absorption, bypassing hepatic first-pass metabolism. In the smoked route, the metabolic pathway shifts from monoamine oxidase-dependent to CYP-dependent: CYP2D6 becomes the primary metabolic enzyme.[6] Co-inhaled β-carbolines further extend DMT's presence by inhibiting residual MAO-A activity in lung and liver tissue.[3] At the receptor level, combined full 5-HT₂A agonism alongside sigma-1 receptor and TAAR1 engagement produces Changa's characteristic content-rich visual phenomena and transpersonal states.[2]
What it changes
A factorial dose-escalation study of transmucosal DMT combined with harmine demonstrated bidirectional pharmacokinetic interaction: harmine reduced DMT metabolism while DMT altered harmine pharmacokinetics.[20] Neuroimaging of oral ayahuasca — the closest studied structural analog — shows increased delta and theta oscillations in amygdala and hippocampus, decreased alpha activity in the default mode network, and stimulation of visual-association cortex.[21] Post-acute changes include reduced glutamate in the posterior cingulate cortex and enhanced connectivity to the anterior cingulate, correlating with mindfulness enhancement capacities.[22]
- Whether co-inhaled β-carbolines achieve sufficient systemic concentration for meaningful MAO-A inhibition, or act primarily locally in pulmonary tissue, remains uncharacterized.
- The impact of CYP2D6 pharmacogenomic variation — particularly poor-metabolizer phenotypes — on Changa duration and intensity has not been studied.
- Whether smoked Changa produces neuroimaging signatures comparable to oral ayahuasca is unknown.
Subjective Effects[edit]
The Changa experience is shaped primarily by the DMT-to-MAOI ratio in the blend. A high-MAOI preparation produces a longer, more structured arc with gradual onset and sustained narrative coherence; a low-MAOI blend more closely resembles pure freebase DMT in its abrupt intensity. Set, setting, and inhalation technique further modulate the experience — deep, sustained inhalation vaporizes DMT more completely than rapid draws, producing fuller effects at the same dose.
Phenomenologically, Changa occupies the space between freebase DMT and oral ayahuasca. It shares DMT's perceptual intensity and transpersonal depth but compresses ayahuasca's multi-hour duration into a 15–40-minute window. Compared with smoked 5-MeO-DMT, which tends toward undifferentiated ego dissolution, Changa's DMT base characteristically produces structured, content-rich visual and entity-contact phenomena.
Effect Grid
A full psychedelic state develops with vivid geometry, environmental patterning, and color alteration dominating the visual field. Internal hallucinations emerge — eyes-closed imagery becomes structured and immersive. Ego dissolution begins, temporal distortion is pronounced, and thought disorganization replaces linear cognition. Entity contact phenomena may begin at the upper range of this tier.
Body effects intensify: a strong body high with vibrations and buzzing, spontaneous body sensations, and clear motor control impairment. Pupil dilation is pronounced. Nausea is less common than with oral ayahuasca, as the smoked route bypasses the gastrointestinal tract.
This is the standard Changa experience at 25–50 mg DMT content (50–200 mg blend). Duration extends to 20–40 minutes. The MAOI component produces a more gradual onset and greater situational coherence than equivalent freebase DMT doses. Users cannot reliably determine their blend's DMT content without analytical testing — dose titration is inherently imprecise.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color enhancement · Spatial disorientation · Symmetrical texture repetition · Tracers · Visual breathing · Visual drifting · Visual morphing · Ganzfeld effect · Vestibular distortion · Depth perception distortion · Perspective distortion · Visual diffraction · Visual haze / noise · Visual melting · Proprioceptive distortion · After-images · Auditory distortion · Light sensitivity · Music enhancement · Peripheral vision distortion · Sound sensitivity · Auditory enhancement · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Touch enhancement · Visual magnification · Dreaming enhancement · Visual processing acceleration · Olfactory enhancement · Flashbacks · Internal hallucinations · External hallucinations · Object transformations · Visual recursion · Object activation · Perspective hallucinations · Environmental orbism / cubism · Visual processing suppression · Auditory hallucinations · Visual flipping · Visual scenery slicing · Shadow people · Persisting hallucinations
Visual breathing · Visual drifting · Visual morphing · Ganzfeld effect · Vestibular distortion · Depth perception distortion · Perspective distortion · Visual diffraction · Visual haze / noise · Visual melting · Proprioceptive distortion · After-images · Auditory distortion · Light sensitivity · Music enhancement · Peripheral vision distortion · Sound sensitivity · Auditory enhancement · Auditory misinterpretation · Peripheral misidentification · Synesthesia · Touch enhancement · Visual magnification · Dreaming enhancement · Visual processing acceleration · Olfactory enhancement · Flashbacks · Internal hallucinations · External hallucinations · Object transformations · Visual recursion · Object activation · Perspective hallucinations · Environmental orbism / cubism · Visual processing suppression · Auditory hallucinations · Visual flipping · Visual scenery slicing · Shadow people · Persisting hallucinations
Body high · Wakefulness · Pupil dilation · Body scan awareness · Body schema distortion · Stimulation · Dizziness · Heart rate perception changes · Kundalini-like energy · Breathing alteration · Nausea · Muscle tension · Physical fatigue · Appetite suppression · Tactile euphoria · Bodily lightness · Bodily pressures · Excessive sweating · Trembling · Involuntary body movements · Nystagmus (eye wobbles) · Restlessness · Bodily heaviness · Laughter fits · Vasoconstriction · Insomnia · Vomiting · Bodily dissociation · Tactile hallucination
Body scan awareness · Body schema distortion · Stimulation · Dizziness · Heart rate perception changes · Kundalini-like energy · Breathing alteration · Nausea · Muscle tension · Physical fatigue · Appetite suppression · Tactile euphoria · Bodily lightness · Bodily pressures · Excessive sweating · Trembling · Involuntary body movements · Nystagmus (eye wobbles) · Restlessness · Bodily heaviness · Laughter fits · Insomnia · Vomiting · Bodily dissociation · Tactile hallucination
Immersion enhancement · Novelty enhancement · Pattern recognition enhancement · Thought connectivity · Thought disorganization · Cognitive euphoria · Conceptual thinking · Focus suppression · Information processing suppression · Introspection enhancement · Openness enhancement · Analysis suppression · Cognitive flexibility · Language suppression · Memory fragmentation · Multiple thought streams · Thought acceleration · Increased nature relatedness · Memory suppression · Motivation suppression · Synchronicity · Thought loops · Creativity enhancement · Cognitive dysphoria · Cognitive fatigue · Memory replays · Analysis enhancement · Humor enhancement · Information processing enhancement · Thought deceleration · Amnesia · Delirium · Delusions
Thought connectivity · Thought disorganization · Cognitive euphoria · Conceptual thinking · Focus suppression · Information processing suppression · Introspection enhancement · Openness enhancement · Analysis suppression · Cognitive flexibility · Language suppression · Memory fragmentation · Multiple thought streams · Thought acceleration · Increased nature relatedness · Memory suppression · Motivation suppression · Synchronicity · Thought loops · Creativity enhancement · Cognitive dysphoria · Cognitive fatigue · Memory replays · Analysis enhancement · Humor enhancement · Information processing enhancement · Thought deceleration · Delirium · Delusions
Euphoria · Simultaneous emotions · Empathy enhancement · Anxiety suppression · Dysphoria
Dysphoria
Emotional susceptibility · Sociability suppression · Automaticity · Compulsive behavior reduction · Disinhibition · Social connection · Flow state · Boundary dissolution · Cognitive disconnection · Identity alteration · Ego dissolution · Telepathic feelings
Disinhibition · Social connection · Flow state · Boundary dissolution · Cognitive disconnection · Identity alteration · Ego dissolution · Telepathic feelings
Time cessation
Transpersonal visions · Non-dual awareness · Voidness · Death-rebirth sequence · Cessation · Near-death experience · Transpersonal memory access
Cessation · Near-death experience · Transpersonal memory access
Timeline · by preparation
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- 1 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- psilo · LSD · mesc
No adverse event case reports specifically attributable to Changa as a named preparation exist in the published literature. All safety data below are extrapolated from ayahuasca (oral DMT + MAOI), pure smoked or intravenous DMT, and β-carboline pharmacology. The risk profile of smoked Changa may differ meaningfully from these analogues given its distinct route and co-inhalation of MAOI compounds.
Toxicity
Ayahuasca is characterized as generally safe in healthy populations under controlled conditions, based on a systematic review of 78 articles.[8] No controlled toxicity data exist for Changa as a preparation.
Cardiovascular: Intravenous DMT produces dose-dependent increases in heart rate, blood pressure, pupil dilation, and body temperature.[23] Oral ayahuasca raises diastolic blood pressure by approximately 9 mmHg at high doses.[24] No cardiovascular data specific to smoked Changa exist.
Neurological: harmaline produces generalized tremor in animal models and is the standard experimental model of essential tremor.[25] At high parenteral doses in rats, harmaline causes selective brain cell degeneration through sustained excitotoxicity.[26] Direct relevance at smoked Changa doses is not established.
Rhabdomyolysis: One case report documents severe muscle breakdown (creatine kinase 110,659 IU/L) with stage 3 acute kidney injury (creatinine 13.6 mg/dL) following ayahuasca ingestion.[27]
Reproductive toxicity: Ayahuasca at 4–8× human-equivalent doses in rats caused maternal deaths, fetal anomalies, and increased embryolethality.[28]
Hepatic: A cohort of 22 long-term ayahuasca users showed no significant changes in liver function tests after a year or more of at-least-twice-monthly use.[29]
Contaminant and adulterant risk: As an informally produced preparation, Changa carries several contamination risks:
- Residual solvents: Incomplete evaporation of extraction solvents (naphtha, diethyl ether) presents pulmonary and liver toxicity risk on inhalation.
- Unstandardized MAOI content: Actual harmine and harmaline concentrations are neither disclosed nor tested, leading to unpredictable duration and intensity.
- Herb substitution: Base herbs vary by recipe with no standardization; misidentified plants are a theoretical concern.
- No laboratory testing: No commercially produced Changa has been subjected to accredited analysis or has a Certificate of Analysis.
- Synthetic adulterants: Addition of synthetic compounds to informally produced psychoactive preparations is a recognized risk in the broader novel psychoactive substance market.[11]
Psychological Risks
Overwhelming, terrifying experiences represent the primary acute psychological risk. Intravenous DMT at fully psychoactive doses produces hallucinations, loss of thought control, and dissociative states in a proportion of participants.[7]
The Global Ayahuasca Survey (n = 10,836) reported mental health adverse effects in the weeks or months following use in 55.9% of respondents; however, 88% of those considered them part of a positive growth process.[30] Only 2.3% required medical attention for acute adverse effects.
Nausea and vomiting, reported by 69.9% of ayahuasca users, are expected to be substantially less common via the smoked route, though no comparative data exist.[30]
Prolonged derealization, depersonalization, or triggering of psychotic episodes in predisposed individuals have been reported in case series but remain poorly characterized in frequency.[8] Individuals with personal or family history of psychotic disorders are at elevated risk.
Tolerance & Dependence
Tolerance: Psychedelics acting on serotonin pathways develop rapid functional tolerance within a session — effects diminish on immediate re-administration.[7] Tolerance does not build across sessions at typical use frequencies.[31] No tolerance studies specific to Changa exist.
Dependence: No evidence of physical dependence on DMT or ayahuasca has been published. Psychological dependence risk appears low.[8] DMT is not associated with compulsive use patterns.
Cross-tolerance: DMT shares cross-tolerance with other classical psychedelics (psilocybin, LSD, mescaline) through shared serotonin pathway activation.[2]
Withdrawal: No withdrawal for DMT, β-carboline alkaloids, or ayahuasca has been documented.
Drug Interactions
The presence of reversible MAO-A inhibitors in Changa creates a distinct interaction profile that differs from pure DMT.
Serotonergic medications (high severity): Combining with SSRIs or SNRIs risks serotonin syndrome — a potentially life-threatening overheating and seizure response — through two mechanisms: MAO-A inhibition raises serotonin levels, and SSRIs such as fluoxetine or paroxetine also block liver enzymes that clear DMT and harmine, markedly increasing their levels in the bloodstream.[32] SSRIs are among the most concerning interactions for psychedelics generally.[9]
Irreversible MAOIs (critical severity): Combining Changa with irreversible MAOIs (phenelzine, tranylcypromine, selegiline) is potentially life-threatening due to compounded, non-reversible monoamine oxidase inhibition and serotonergic surge. safety citation needed
Tramadol: serotonin reuptake inhibitor combined with MAO-A inhibition creates serotonin syndrome risk, with additional seizure threshold reduction.[9]
Triptans: As serotonergic agonists, triptans carry additive risk when combined with MAOI-containing preparations.[9]
Lithium: Seizures have been reported with lithium-psychedelic combinations; the mechanism remains unclear.[9]
Tyramine-containing foods: β-Carbolines as MAO-A inhibitors theoretically impair dietary tyramine metabolism, which can cause dangerous blood pressure spikes. However, reversible MAO-A inhibitors carry substantially lower tyramine risk than irreversible MAOIs.[32] No case reports of hypertensive crisis from tyramine in the context of Changa or harmaline-containing preparations have been published.
Contraindications
Pregnancy (absolute): Reproductive toxicity at suprapharmacological doses in rats — including maternal death, embryolethality, and fetal anomalies — contraindicates use during pregnancy.[28]
Concurrent serotonergic medication (absolute): SSRIs, SNRIs, irreversible MAOIs, tramadol, and triptans are contraindicated due to serotonin syndrome risk. Pharmacokinetic modelling shows markedly increased DMT and harmine in the bloodstream when combined with CYP2D6-inhibiting SSRIs.[32]
Lithium therapy (absolute): Seizure risk with psychedelic co-administration.[9]
Psychotic spectrum disorders (absolute): Personal or family history of schizophrenia, schizoaffective disorder, or other psychotic conditions. Psychedelics may trigger or worsen psychotic episodes in predisposed individuals.[8]
Cardiovascular disease (relative): DMT raises heart rate and blood pressure in a dose-dependent manner.[23] Those with uncontrolled hypertension, recent heart attack, or unstable cardiovascular conditions should avoid use.
Hepatic impairment (relative): Liver enzymes are the primary means of clearing both DMT and harmine when smoked.[6] Impaired liver function may prolong exposure.
CYP2D6 poor metabolizer phenotype (relative): Poor metabolizers may experience substantially prolonged DMT and harmine exposure through reduced hepatic clearance. safety citation needed
Preparations[edit]
Blend composition
A Changa blend is defined by three variables: the mass of freebase DMT, the quantity of MAOI-containing plant material, and the choice of carrier herb. Community recipes typically express DMT loading as a percentage of total blend weight.
A high-MAOI blend contains more β-carboline material relative to DMT. These blends produce longer duration (toward 30–40 minutes), more gradual onset, and greater narrative coherence. A low-MAOI blend produces shorter total duration and more abrupt onset, closer in character to pure freebase DMT.
Pipe or water pipe
Pipe or water pipe is the most common administration method. Changa is loaded into a bowl and inhaled as smoke. Onset occurs within 1–2 minutes; peak effects at 5–15 minutes; total duration 15–40 minutes depending on MAOI content and dose.[1] Deep, sustained inhalation vaporizes DMT more completely than rapid puffs.
Joint or rolled format
Joint or rolled format was part of Palmer's original design: a preparation smokeable without specialized glassware.[1] This format typically delivers DMT less efficiently than a pipe due to sidestream loss and combustion temperature variation, potentially producing a milder experience from the same blend. citation needed
Vaporizer
Vaporizer use is less common and requires devices capable of reaching freebase DMT's vaporization temperature. Too low and DMT fails to vaporize; too high and thermal degradation reduces potency. No published data on vaporizer-specific pharmacokinetics for Changa exist. citation needed
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Harm Reduction[edit]
Forms & Identification
No laboratory testing infrastructure exists for Changa. The preparation carries no Certificate of Analysis, batch labeling, or standardized potency disclosure — the DMT content and MAOI concentration of any batch are unknown. Reagent testing with Ehrlich reagent can confirm the presence of indole alkaloids (a purple color change indicates DMT) but cannot quantify concentration or identify the β-carboline profile. Marquis and Mecke reagents may provide supplementary data but are not definitive for Changa's complex alkaloid mixture. Every new batch should be treated as unknown potency.
Guidelines
Practical guidance
- Start low: With any new batch, begin with a single shallow inhalation to gauge potency before committing to a full dose. Changa potency varies dramatically between preparations.
- Allow onset: Wait at least 5 minutes after the first inhalation before considering additional doses. The MAOI component may delay peak effects compared to pure freebase DMT.
- Use a sitter: A sober companion who understands the preparation's effects and duration should remain present throughout. Agree on a non-intervention protocol in advance — the sitter intervenes only for physical safety.
- Prepare the space: Remove sharp objects, secure elevated surfaces, and ensure the user is seated or lying down before inhalation. Fire safety: use a non-flammable surface beneath the pipe; Changa is a combustible herbal material.
- Hydrate beforehand: Ensure adequate hydration before the session. Do not attempt to drink during peak effects.
- Time commitment: Allow at least 60 minutes for the full experience including residual effects, even though peak duration is 15–40 minutes.
Set & Setting
Changa produces rapid-onset, intense psychedelic effects that may include complete loss of contact with ordinary reality. A calm, familiar environment with minimal sensory stimulation is strongly advised. A sober, experienced sitter should be present throughout — particularly for first-time use or when trying a new batch.
Avoid use in public spaces, near water, at height, or while operating vehicles or machinery. Acute anxiety, unresolved distress, or an unstable mindset elevates the risk of an overwhelmingly negative experience.
Aftercare & integration.
Post-experience care
Acute effects of Changa typically resolve within 40 minutes, but residual perceptual shifts, emotional sensitivity, and fatigue may persist for several hours. Allow time for quiet reflection before returning to demanding activities. Light food and water help restore baseline.
Intense or challenging experiences benefit from verbal processing — talking through what happened with a trusted person or integration-trained therapist within the first few days. Journaling while details remain fresh supports later integration. Avoid making significant life decisions in the immediate aftermath of a high-dose psychedelic experience.
Recovery & Support
Support resources
DMT is not associated with physical dependence or compulsive use patterns. However, individuals who find themselves using Changa with increasing frequency or relying on the experience to manage emotional distress should consider speaking with a mental health professional.
- SAMHSA National Helpline: 1-800-662-4357 (US, free, confidential, 24/7)
- Fireside Project: 62-FIRESIDE (623-473-7433) — psychedelic peer support line
- Integration directories: MAPS (maps.org) and Psychedelic Support (psychedelic.support)
If persistent derealization, depersonalization, or anxiety follows use, seek professional evaluation promptly. These effects are uncommon but documented in case series following DMT and ayahuasca use.[8]
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
- Severe panic or psychotic symptoms: screaming, violent agitation, attempting to flee, complete disorientation
- Seizure activity
- Chest pain, difficulty breathing, or irregular heartbeat
- Unresponsiveness or loss of consciousness
- Signs of serotonin syndrome: high temperature, rigid muscles, rapid heartbeat, agitation
Immediate steps
- 1. Ensure the person's physical safety — move them away from hazards, place on their side if unconscious.
- 2. Speak calmly and reassuringly. Remind them of who they are, where they are, and that the effects are temporary.
- 3. If conscious but in severe distress, reduce sensory input: dim lights, lower noise, offer a blanket.
- 4. Call emergency services (911 / 112 / local equivalent) if the person is unconscious, seizing, experiencing chest pain, or showing signs of serotonin syndrome.
What to tell the dispatcher
State that the person smoked a psychedelic preparation containing DMT and monoamine oxidase inhibitors. Report the approximate time of use, symptoms observed, and any medications the person takes regularly. Good Samaritan laws in many jurisdictions protect callers reporting drug-related emergencies.
Reversal agents
No specific reversal agent for DMT or β-carboline alkaloids exists. Benzodiazepines may be administered by medical professionals for severe agitation or seizures. Serotonin syndrome requires emergency medical treatment and cannot be managed on-scene.
Legal Status[edit]
Because Changa contains extracted freebase DMT — a Schedule I controlled substance under US federal law and the 1971 UN Convention on Psychotropic Substances — it is illegal in all jurisdictions where DMT is controlled, regardless of the legal status of its MAOI or carrier herbs.[33] Unlike traditional ayahuasca brew, which occupies a legal grey zone as an organic plant preparation in some jurisdictions, Changa's use of extracted freebase DMT is unambiguously covered by scheduling of the pure compound. In the United States, DMT possession and manufacture are federal felonies under the Controlled Substances Act; Oregon and several municipalities have decriminalized personal-use possession, but no state has legalized manufacture or sale. In Canada, DMT is Schedule III under the CDSA. In the UK, it is Class A under the Misuse of Drugs Act 1971 — up to 7 years for possession, life imprisonment for supply. In Australia, it is Schedule 9 (prohibited substance). Religious exemptions granted to ayahuasca churches (Santo Daime, União do Vegetal) do not extend to smoked Changa. The MAOI plants — B. caapi and P. harmala — are not DEA-scheduled in the United States, though P. harmala is restricted for cultivation as invasive in several states and prohibited for human consumption in Louisiana.[15] Harmaline is controlled in some European jurisdictions, including Hungary and Latvia.citation needed Standard immunoassay drug panels do not detect DMT or β-carboline alkaloids; specialized GC-MS or LC-MS/MS analysis can detect DMT, harmine, and harmaline in urine.[34][6]
Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- 1 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- psilo · LSD · mesc
No adverse event case reports specifically attributable to Changa as a named preparation exist in the published literature. All safety data below are extrapolated from constituent-level studies of ayahuasca (oral DMT + MAOI), pure smoked or intravenous DMT, and β-carboline alkaloid pharmacology. The risk profile of smoked Changa may differ meaningfully from these analogues given the distinct route and co-inhalation of MAOI compounds.
Toxicity
Ayahuasca (oral DMT + harmala alkaloids) is characterized as generally safe in healthy populations under controlled conditions, based on a systematic review of 78 articles.[8] No LD₅₀ data for DMT in humans have been published. No controlled toxicity data exist for Changa as a preparation.
Cardiovascular: Intravenous DMT produces dose-dependent increases in heart rate, blood pressure, pupil dilation, and rectal temperature.[23] Oral ayahuasca increases diastolic blood pressure by approximately 9 mmHg at high doses.[24] No cardiovascular data specific to smoked Changa exist.
Neurological: harmaline produces generalized tremor in animal models and serves as the standard experimental model of essential tremor.[25] At high parenteral doses in rats, harmaline causes selective Purkinje cell degeneration via sustained climbing-fiber excitotoxicity.[26] Direct human relevance at smoked Changa doses is not established.
Rhabdomyolysis: A single case report documents severe rhabdomyolysis (creatine kinase 110,659 IU/L) with stage 3 acute kidney injury (creatinine 13.6 mg/dL) following ayahuasca ingestion.[27]
Reproductive toxicity: Ayahuasca administered at 4–8× human-equivalent doses in rats caused maternal deaths, fetal anomalies, and increased embryolethality.[28]
Hepatic: A cohort of 22 volunteers consuming ayahuasca at least twice monthly for a year or longer showed no significant alterations in liver function tests (ALT, AST, bilirubin, creatinine).[29]
Contaminant and adulterant risk: As an informally produced preparation, Changa carries several contamination vectors:
- Residual solvents: Home DMT extractions may retain naphtha, diethyl ether, or other volatile solvents if evaporation is incomplete, presenting pulmonary and hepatic toxicity risk on inhalation.
- Unstandardized MAOI content: Actual harmine and harmaline concentrations are neither disclosed nor tested, leading to unpredictable duration and intensity.
- Herb substitution: Base herbs vary by recipe with no standardization; misidentified plants are a theoretical concern.
- No laboratory testing: No commercially produced Changa has been subjected to ISO/IEC-accredited analysis or Certificate of Analysis. No state or national testing program covers this preparation.
- Synthetic adulterants: Although not documented for Changa specifically, addition of synthetic compounds to informally produced psychoactive preparations is a recognized risk in the broader novel psychoactive substance market.[11]
Psychological Risks
Overwhelming, terrifying psychedelic experiences represent the primary acute psychological risk. Intravenous DMT at fully psychoactive doses (0.2–0.4 mg/kg) produces hallucinations, loss of thought control, and dissociative states in a proportion of participants.[7]
The Global Ayahuasca Survey (n = 10,836) reported mental health adverse effects in the weeks or months following use in 55.9% of respondents; however, 88% of those reporting such effects considered them part of a positive growth process.[30] Only 2.3% required medical attention for acute adverse effects. Nausea and vomiting, reported by 69.9%, are characteristic of the oral ayahuasca route; the smoked Changa route is expected to produce substantially less emesis, though no comparative data exist.[30]
Persistent psychological effects — including prolonged derealization, depersonalization, or precipitation of psychotic episodes in predisposed individuals — have been reported in case series but remain poorly characterized in frequency.[8] Individuals with personal or family history of psychotic disorders are at elevated risk.
Tolerance & Dependence
Tolerance: Classical psychedelics acting at 5-HT₂A receptors develop rapid functional tolerance within a session, with effects diminishing on immediate re-administration.[7] Desensitization occurs at 5-HT₂C but not 5-HT₂A receptors, consistent with DMT's absence of functional tolerance across sessions at typical use frequencies.[31] No tolerance studies specific to Changa exist.
Dependence: No evidence of physical dependence on DMT or ayahuasca has been published. Psychological dependence risk appears low.[8] DMT is not associated with compulsive use patterns.
Cross-tolerance: cross-tolerance exists between DMT and other classical psychedelics (psilocybin, LSD, mescaline) via shared 5-HT₂A receptor mechanisms.[2]
Withdrawal: No documented withdrawal for DMT, β-carboline alkaloids, or ayahuasca exists.
Drug Interactions
The presence of reversible MAO-A inhibitors in Changa creates a distinct interaction profile differing from pure DMT.
Serotonergic medications (high severity): Concurrent use with SSRIs or SNRIs risks serotonin syndrome through dual mechanisms: pharmacodynamic potentiation via MAO-A inhibition and pharmacokinetic inhibition of CYP2D6 by SSRIs (fluoxetine, paroxetine), markedly increasing both DMT and harmine plasma levels.[32] SSRIs are among the most concerning drug interactions for psychedelics generally.[9]
Irreversible MAOIs (critical severity): Combining Changa with irreversible MAOIs (phenelzine, tranylcypromine, selegiline) is potentially life-threatening due to compounded, non-reversible monoamine oxidase inhibition and serotonergic surge. safety citation needed
Tramadol: serotonin reuptake inhibitor combined with MAO-A inhibition creates serotonin syndrome risk, with additional seizure threshold reduction.[9]
Triptans: As serotonergic agonists, triptans carry additive risk when combined with MAOI-containing preparations.[9]
Lithium: Seizures have been reported with lithium-psychedelic combinations; the mechanism remains unclear.[9]
Tyramine-containing foods: β-Carbolines as MAO-A inhibitors theoretically impair dietary tyramine metabolism, potentially causing hypertensive crisis. However, reversible MAO-A inhibitors carry substantially lower tyramine risk than irreversible MAOIs.[32] No clinical case reports of hypertensive crisis from tyramine in the context of Changa or harmaline-containing preparations have been published.
Contraindications
Pregnancy (absolute): Reproductive toxicity at suprapharmacological doses in rats — including maternal death, embryolethality, and fetal anomalies — contraindicates use during pregnancy.[28]
Concurrent serotonergic medication (absolute): SSRIs, SNRIs, irreversible MAOIs, tramadol, and triptans are contraindicated due to serotonin syndrome risk. PBPK modelling demonstrates markedly increased DMT and harmine plasma concentrations with CYP2D6-inhibiting SSRIs.[32]
Lithium therapy (absolute): Seizure risk with psychedelic co-administration.[9]
Psychotic spectrum disorders (absolute): Personal or family history of schizophrenia, schizoaffective disorder, or other psychotic spectrum conditions. Psychedelics may precipitate or exacerbate psychotic episodes in predisposed individuals.[8]
Cardiovascular disease (relative): DMT produces dose-dependent increases in heart rate and blood pressure.[23] Individuals with uncontrolled hypertension, recent myocardial infarction, or unstable cardiovascular conditions should avoid use.
Hepatic impairment (relative): CYP2D6 is the primary metabolic enzyme for DMT and harmine in the smoked route.[6] Impaired liver function may prolong exposure.
CYP2D6 poor metabolizer phenotype (relative): Poor metabolizers may experience substantially prolonged DMT and harmine exposure via reduced hepatic clearance. safety citation needed
Preparations[edit]
Blend composition
Changa blends are defined by three variables: the mass of freebase DMT, the quantity of MAOI-containing plant material, and the choice of carrier herb. Community recipes typically express DMT loading as a percentage of total blend weight. The MAOI component — most commonly B. caapi leaf, P. harmala seed extract, or herb infused with P. harmala extract — determines how strongly the preparation extends and modulates DMT's effects.
A high-MAOI blend contains a greater proportion of β-carboline material relative to DMT. These blends produce longer duration (toward the 30–40-minute end of the range), more gradual onset, and greater narrative coherence. A low-MAOI blend more closely approximates the tempo and intensity of pure freebase DMT, with shorter total duration and more abrupt onset.
Pipe or water pipe
Pipe or water pipe is the most common administration method. A measured quantity of Changa blend is loaded into a pipe bowl or water pipe and inhaled as smoke. Community-reported parameters: onset within 1–2 minutes, peak effects at 5–15 minutes, total duration 15–40 minutes depending on MAOI content and dose.[1] Inhalation technique significantly affects intensity — deep, sustained draws vaporize DMT more completely than rapid puffs.
Joint or rolled format
Joint or rolled format was part of Palmer's original design intent: a preparation that could be smoked without specialized glassware.[1] Changa can be rolled alone or blended with additional non-psychoactive herb. This format typically delivers DMT less efficiently than a pipe due to sidestream loss and combustion temperature variation, potentially producing a milder experience from the same blend. citation needed
Vaporizer
Vaporizer use with Changa is less common and requires devices capable of reaching the vaporization temperature of freebase DMT. Temperature control is critical: too low and DMT fails to vaporize; too high and thermal degradation reduces potency. No published data on vaporizer-specific pharmacokinetics for Changa exist. citation needed
Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.
Harm Reduction[edit]
Forms & Identification
No laboratory testing infrastructure exists for Changa. The preparation carries no Certificate of Analysis, batch labeling, or standardized potency disclosure — the DMT content and MAOI concentration of any given batch are unknown to the user. Reagent testing with Ehrlich reagent can confirm the presence of indole alkaloids (purple color change indicates DMT) but cannot quantify concentration or identify the specific β-carboline profile. Marquis and Mecke reagents may provide supplementary data but are not definitive for Changa's complex alkaloid mixture. Every new batch should be treated as an unknown-potency preparation.
Guidelines
Practical guidance
- Start low: With any new batch, begin with a single shallow inhalation to gauge potency before committing to a full dose. Changa potency varies dramatically between preparations.
- Allow onset: Wait at least 5 minutes after the first inhalation before considering additional doses. The MAOI component may delay peak effects compared to pure freebase DMT.
- Use a sitter: A sober companion who understands the preparation's effects and duration should remain present throughout. Agree on a non-intervention protocol in advance — the sitter intervenes only for physical safety.
- Prepare the space: Remove sharp objects, secure elevated surfaces, and ensure the user is seated or lying down before inhalation. Fire safety: use a non-flammable surface beneath the pipe; Changa is a combustible herbal material.
- Hydrate beforehand: Ensure adequate hydration before the session. Do not attempt to drink during peak effects.
- Time commitment: Allow at least 60 minutes for the full experience including residual effects, even though peak duration is 15–40 minutes.
Set & Setting
Changa produces rapid-onset, intense psychedelic effects that may include complete loss of contact with ordinary reality. A calm, familiar environment with minimal sensory stimulation is strongly advised. A sober, experienced sitter should be present throughout — particularly for first-time users or when trying a new batch.
Avoid use in public spaces, near water, at height, or while operating vehicles or machinery. Psychological preparedness matters: acute anxiety, unresolved distress, or an unstable mindset elevates the risk of an overwhelmingly negative experience.
Aftercare & integration.
Post-experience care
Acute effects of Changa typically resolve within 40 minutes, but residual perceptual shifts, emotional sensitivity, and fatigue may persist for several hours. Allow time for quiet reflection before returning to demanding activities. Light food and water help restore baseline.
Intense or challenging experiences benefit from verbal processing — talking through what happened with a trusted person or integration-trained therapist within the first few days. Journaling while details remain fresh supports later integration. Avoid making significant life decisions in the immediate aftermath of a high-dose psychedelic experience.
Recovery & Support
Support resources
DMT is not associated with physical dependence or compulsive use patterns. However, individuals who find themselves using Changa with increasing frequency or relying on the experience to manage emotional distress should consider speaking with a mental health professional.
- SAMHSA National Helpline: 1-800-662-4357 (US, free, confidential, 24/7)
- Fireside Project: 62-FIRESIDE (623-473-7433) — psychedelic peer support line
- Integration directories: MAPS (maps.org) and Psychedelic Support (psychedelic.support)
If persistent derealization, depersonalization, or anxiety follows use, seek professional evaluation promptly. These effects are uncommon but documented in case series following DMT and ayahuasca use.[8]
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
- Severe panic or psychotic symptoms: screaming, violent agitation, attempting to flee, complete disorientation
- Seizure activity
- Chest pain, difficulty breathing, or irregular heartbeat
- Unresponsiveness or loss of consciousness
- Signs of serotonin syndrome: high temperature, rigid muscles, rapid heartbeat, agitation
Immediate steps
- 1. Ensure the person's physical safety — move them away from hazards, place on their side if unconscious.
- 2. Speak calmly and reassuringly. Remind them of who they are, where they are, and that the effects are temporary.
- 3. If conscious but in severe distress, reduce sensory input: dim lights, lower noise, offer a blanket.
- 4. Call emergency services (911 / 112 / local equivalent) if the person is unconscious, seizing, experiencing chest pain, or showing signs of serotonin syndrome.
What to tell the dispatcher
State that the person smoked a psychedelic preparation containing DMT and monoamine oxidase inhibitors. Report the approximate time of use, symptoms observed, and any medications the person takes regularly. Good Samaritan laws in many jurisdictions protect callers reporting drug-related emergencies.
Reversal agents
No specific reversal agent for DMT or β-carboline alkaloids exists. Benzodiazepines may be administered by medical professionals for severe agitation or seizures. Serotonin syndrome requires emergency medical treatment and cannot be managed on-scene.
Legal Status[edit]
Because Changa contains extracted freebase DMT — a Schedule I controlled substance under US federal law and the 1971 United Nations Convention on Psychotropic Substances — the preparation is illegal in all jurisdictions where DMT is controlled, regardless of the legal status of its MAOI or carrier herbs.[33] Unlike traditional ayahuasca brew, which occupies a legal grey zone as an organic plant preparation in some jurisdictions, Changa's use of extracted freebase DMT falls unambiguously under scheduling of the pure compound. Religious exemptions granted to ayahuasca churches (Santo Daime, União do Vegetal) do not extend to smoked Changa preparations.
Jurisdiction table
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States (federal) | Schedule I (CSA, placed 1971) | Possession, manufacture, and distribution are federal felonies. No accepted medical use under federal law.[33] |
| United States (state) | Variable | Oregon Measure 110 (2020) decriminalized personal-use possession of controlled substances including DMT. Denver, Oakland, Santa Cruz, and other municipalities have passed deprioritization resolutions. No state has legalized DMT manufacture or sale. |
| Canada | Schedule III (CDSA) | Religious exemptions for some ayahuasca organizations do not extend to Changa. |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Maximum 7 years imprisonment for possession; life imprisonment for supply. |
| Germany | Controlled (Betäubungsmittelgesetz) | No medical-use exception for DMT. |
| Netherlands | List I (Opiumwet) | DMT is List I. Ayahuasca has received some enforcement tolerance; Changa has no such precedent. |
| Australia | Schedule 9 (TGA Poisons Standard) | Prohibited substance. No medical-use pathway outside clinical trials. |
| International | Schedule I (UN Convention 1971) | Plant-source DMT occupies a grey zone; extracted freebase DMT is unambiguously scheduled. |
MAOI component plants
Banisteriopsis caapi: Not DEA-scheduled in the United States. The plant is legal to cultivate and possess; preparations intended for psychoactive consumption occupy a legal grey area.
Peganum harmala (Syrian rue): Not DEA-scheduled. Seeds are legally sold in the United States. USDA restricted importation as of March 2022.[15] Louisiana prohibits P. harmala for human consumption (Act No. 159, effective August 2005). Arizona, California, Colorado, Nevada, New Mexico, and Oregon restrict cultivation as an invasive species.[15]
Harmala alkaloids: harmaline is controlled in some European jurisdictions (including Hungary and Latvia). Harmine and harmaline are not explicitly scheduled under UN conventions. citation needed
Analog and detection considerations
The US Federal Analogue Act (21 USC §813) may apply to β-carboline alkaloids when sold for human consumption, as they are structurally related to controlled tryptamines. This has not been tested in court for Changa components specifically.
Standard immunoassay workplace drug panels do not screen for DMT or β-carboline alkaloids. Specialized GC-MS or LC-MS/MS can detect DMT, harmine, harmaline, and their metabolites in urine.[34] DMT's primary urinary metabolite, indole-3-acetic acid (IAA), is endogenous and non-specific; unmetabolized DMT is detectable in urine following the smoked route.[6]
Frequently asked questions
What is Changa?
Changa is a smokeable psychedelic preparation combining freebase DMT with β-carboline MAOI plant material. It adapts the oral ayahuasca mechanism to inhalation, producing effects lasting 15–40 minutes versus 5–15 for freebase DMT alone.
What are dangerous combinations with Changa?
The highest-severity documented interactions for Changa: Amphetamines (Lethal), MDMA, Amphetamines (Lethal), MDMA, MDA (Lethal), Psychedelics (Lethal), SNRIs (Lethal). See the interactions section for the full list with mechanisms and severity levels.
Is Changa addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Changa: tolerance builds none; full reset takes 1 days; cross-tolerance develops with psilocybin, LSD, mescaline. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcdeEgger K, Aicher HD, Cumming P, Scheidegger M (2024) Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors — Cellular and Molecular Life Sciences doi:10.1007/s00018-024-05353-6
- [3] ^abcWittayakarn N, Tan YM, Choomalaiwong P, et al. (2025) Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans — Toxicological Sciences doi:10.1093/toxsci/kfaf118
- [4]
- [5] ^abcMcKenna DJ, Towers GH, Abbott F (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca — Journal of Ethnopharmacology PMID:6587171
- [6]
references
- [1]
- [2] ^abcdEgger K, Aicher HD, Cumming P, Scheidegger M (2024) Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors — Cellular and Molecular Life Sciences doi:10.1007/s00018-024-05353-6
- [3] ^abcWittayakarn N, Tan YM, Choomalaiwong P, et al. (2025) Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans — Toxicological Sciences doi:10.1093/toxsci/kfaf118
- [4]
- [5] ^abcMcKenna DJ, Towers GH, Abbott F (1984) Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca — Journal of Ethnopharmacology PMID:6587171
- [6]